Marshall Wace’s Ovid Therapeutics OVID Stock Holding History

Marshall Wace’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-917,733	Closed	-$2.04M	–	3589
2026 Q1	$2.04M	Sell	917,733 -353,754	-28%	-$632K	﹤0.01%	1776
2025 Q4	$2.07M	Buy	1,271,487 +487,834	+62%	+$751K	﹤0.01%	1563
2025 Q3	$1.02M	Buy	783,653 +618,932	+376%	+$536K	﹤0.01%	1934
2025 Q2	$54.4K	Buy	+164,721	New	+$49.6K	﹤0.01%	2595
2023 Q3	–	Sell	-30,017	Closed	-$98.5K	–	2550
2023 Q2	$98.5K	Buy	+30,017	New	+$102K	﹤0.01%	2325
2019 Q4	–	Sell	-18,060	Closed	-$59K	–	1971
2019 Q3	$59K	Buy	+18,060	New	+$41K	﹤0.01%	1471

Other funds holding OVID

Jupiter Topco New York $245B AUM

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Marshall Wace's OVID Position: Q2 2026 in Review

Marshall Wace sold out of Ovid Therapeutics (OVID) in Q2 2026, closing a stake of 917,733 shares — an estimated $2.04M sold.

Marshall Wace first reported a position in OVID in Q3 2019 and held it in 6 quarters. The position peaked at $2.07M in Q4 2025. 131 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

Marshall Wace reported no remaining Ovid Therapeutics position as of Q2 2026 after selling out during the quarter.
Marshall Wace sold 917,733 Ovid Therapeutics shares in Q2 2026, an estimated $2.04M.
Marshall Wace first reported a position in Ovid Therapeutics in Q3 2019 and held it in 6 quarters.
Marshall Wace's Ovid Therapeutics position peaked at $2.07M in Q4 2025.
131 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.